Detalhe da pesquisa
1.
Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.
N Engl J Med;
390(15): 1394-1407, 2024 04 18.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38587233
2.
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.
N Engl J Med;
389(12): 1069-1084, 2023 Sep 21.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37622681
3.
Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk.
Diabetes Obes Metab;
22(3): 442-451, 2020 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31903692
4.
Trial design and baseline data for LIRA-PRIME: A randomized trial investigating the efficacy of liraglutide in controlling glycaemia in type 2 diabetes in a primary care setting.
Diabetes Obes Metab;
21(7): 1543-1550, 2019 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30828917
5.
Downregulation but lack of promoter hypermethylation or somatic mutations of the potential tumor suppressor CXXC5 in MDS and AML with deletion 5q.
Eur J Haematol;
90(3): 259-60, 2013 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23190153
6.
Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation.
Oncotarget;
6(11): 9612-26, 2015 Apr 20.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25823822
7.
Predicting response to epigenetic therapy.
J Clin Invest;
124(1): 47-55, 2014 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24382389